Alexion Pharmaceuticals

Alexion Pharmaceuticals is a biopharmaceutical company based in Cheshire, Connecticut. Alexion is traded on the NASDAQ and is listed on the NASDAQ -100. The company specializes in orphan product for treatment of rare and very rare diseases.

History

Alexion was founded in 1992, among others, Leonard Bell, a professor of internal medicine and pathology at Yale University. 2011 took over Alexion Taligen Therapeutics (Cambridge, Massachusetts) and established the Translational Medicine Group to bring new product candidates more rapidly into clinical trials can. Also in 2011 took over Alexion Enobia Pharma ( Montreal, Canada ) and their rights to Asfotase Alpha, a product candidate for the treatment of hypophosphatasia.

Indicators

2013, the company generated a turnover of 1.5 billion U.S. dollars. Alexion has more than 55 offices, including Tokyo, Sydney, Lausanne and Munich and employs over 1800 people worldwide. 2013 has been invested in the research about 279 million U.S. dollars.

Drugs

Eculizumab ( Soliris trade name ) is used to treat paroxysmal nocturnal hemoglobinuria or cPMP for the treatment of molybdenum cofactor deficiency.

Types of business entity International Securities Identification Number Cheshire (Connecticut) NASDAQ-100 Cambridge (Massachusetts) 21st Century Fox Activision Blizzard Adobe Systems Akamai Technologies Altera Analog Devices Applied Materials Automatic Data Processing Baidu Biogen Idec Broadcom Celgene Check Point Comcast DirecTV Discovery Communications Equinix Expedia, Inc. Express Scripts Fiserv Garmin Gilead Sciences Henry Schein Intuit KLA-Tencor Kraft Foods Liberty Global Liberty Media Linear Technology Marriott International Mattel Mylan NetApp Netflix NXP Semiconductors Paychex SanDisk Sigma-Aldrich Staples Inc. Starbucks Tesla Motors TripAdvisor Viacom Vodafone Whole Foods Market Xilinx
46222
de